NKILA: A Potential Drug Target and Biomarker for Nuclear Factor Kappa B (NFKB) Interacting LncRNA

Target Name: NKILA

NCBI ID: G105416157

NKILA

Other Name(s): NF-kappaB interacting lncRNA

NKILA: A Potential Drug Target and Biomarker for Nuclear Factor Kappa B (NFKB) Interacting LncRNA

Nuclear factor kappa B (NFKB) is a protein that plays a crucial role in regulating immune and inflammatory responses. The NFKB signaling pathway is involved in the regulation of various cellular processes, including inflammation, cell survival, and angiogenesis. One of the key components of the NFKB signaling pathway is the interaction between NFKB and its interacting lncRNA, NKILA.

NKILA is a non-coding RNA molecule that is highly expressed in various tissues and cell types. It has been shown to interact with NFKB and to play a role in the regulation of NFKB-mediated signaling pathways. NKILA has also been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

As a potential drug target, NKILA is a promising target for small molecule inhibitors that can modulate the activity of NFKB and its downstream targets. NKILA has been shown to be involved in the regulation of cellular processes that are important for cancer progression, such as cell migration, invasion, and angiogenesis. It has also been shown to be involved in the regulation of inflammation, including the regulation of T cell responses to antigens.

In addition to its potential as a drug target, NKILA is also a potential biomarker for various diseases. The regulation of NFKB and its interacting lncRNA, NKILA, is involved in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, NKILA has been shown to be involved in the regulation of cancer cell growth and survival, and has been used as a potential biomarker for cancer diagnosis and treatment.

The NKILA gene has been shown to encode a protein that is involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. It has been shown to interact with several transcription factors, including NFKB and p53. This interaction between NKILA and these transcription factors suggests that NKILA may be involved in the regulation of cellular processes that are important for the development and progression of various diseases.

In addition to its potential as a drug target and biomarker, NKILA is also of interest as a potential therapeutic approach for the treatment of various diseases. The regulation of NFKB and its interacting lncRNA, NKILA, is involved in the regulation of various cellular processes that are important for the development and progression of many diseases. For example, NKILA has been shown to be involved in the regulation of cancer cell growth and survival, and has been used as a potential biomarker for cancer diagnosis and treatment.

In conclusion, NKILA is a potential drug target and biomarker for NFKB-mediated signaling pathways. Its interaction with NFKB and its downstream targets suggests that NKILA may be involved in the regulation of various cellular processes that are important for the development and progression of many diseases. Further research is needed to determine the full role of NKILA in the regulation of NFKB-mediated signaling pathways and its potential as a drug target and biomarker.

Protein Name: NF-kappaB Interacting LncRNA

The "NKILA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NKILA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets